(NASDAQ: INDP) Indaptus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.74%.
Indaptus Therapeutics's earnings in 2026 is -$20,848,916.On average, 3 Wall Street analysts forecast INDP's earnings for 2026 to be -$14,706,506, with the lowest INDP earnings forecast at -$14,129,780, and the highest INDP earnings forecast at -$15,139,050. On average, 3 Wall Street analysts forecast INDP's earnings for 2027 to be -$10,246,524, with the lowest INDP earnings forecast at -$9,844,699, and the highest INDP earnings forecast at -$10,547,892.
In 2028, INDP is forecast to generate $1,806,865 in earnings, with the lowest earnings forecast at $1,736,007 and the highest earnings forecast at $1,860,008.